Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients

Qiang Wei*, Honghao Wang*, Yanghua Tian, Fangcheng Xu, Xianwen Chen, Kai Wang*

Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China

Abstract

Background: Previous studies have shown a lower incidence of stroke in Parkinson’s disease (PD) patients. The role of the lipids and lipoproteins as risk factors for stroke is uncertain in the lower prevalence of stroke in PD patients.

Objectives: To explore the lipids and lipoproteins serum levels in PD patients.

Methods: A retrospective study was performed on 110 PD patients (PD group), 130 controls with non-cerebrovascular neurological diseases (OD group), 140 acute intracerebral hemorrhage patients (ICH group) and 140 acute cerebral infarction patients (CI group). The records about serum levels of lipids and lipoproteins were analyzed.

Results: There were significant differences for the serum level of triglyceride (F = 5.031, p = 0.002), very low density lipoprotein cholesterol (F = 5.313, p = 0.001), apolipoprotein B (F = 16.038, p < 0.0001) in the four groups. PD group had a significantly lower serum level of triglyceride (TG) than the OD (p = 0.032), ICH (p = 0.00047) and CI (p = 0.001) groups. Very low density lipoprotein cholesterol (VLDL-C) serum level was significantly lower in PD group than in OD (p = 0.039), ICH (p = 0.00021) and CI (p = 0.001) groups. There was a significantly lower serum level of apolipoprotein B (apo B) in PD group than in OD (p = 0.002), ICH (p = 0.0001) and CI (p = 0.0001) groups.

Conclusions: There are reduced serum levels of TG, VLDL-C and apo B in PD patients, which may be related to the decreased prevalence of stroke in PD patients.

Citation: Wei Q, Wang H, Tian Y, Xu F, Chen X, et al. (2013) Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients. PLoS ONE 8(9): e75743. doi:10.1371/journal.pone.0075743

Editor: Pedro Gonzalez-Alegre, University of Iowa Carver College of Medicine, United States of America

Received March 5, 2013; Accepted August 19, 2013; Published September 26, 2013

Copyright: © 2013 Wei et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing interests: The co-author Dr. Kai Wang is a PLOS ONE Editorial Board member, but this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: wangkai1964@126.com
☯ These authors contributed equally to this work.

Introduction

Parkinson’s disease (PD) is an age-related disorder that classically presents with extrapyramidal symptoms of tremor, rigidity, bradykinesia and postural instability, and includes non-motor symptoms such as depression, anxiety, muscular pain and other disturbances. The occurrence of PD is due to the neuronal degeneration of substantia nigra pars compacta, which causes the deficiency of dopaminergic neurotransmission in the basal ganglia [1,2].

PD significantly lowers the quality life of affected patients. Although not confirmed by some authors [3], epidemiological studies seem to show a reduced incidence of stroke in PD patients. Struck et al [4] and Nataraj and Rajput [5] have found a lower prevalence of stroke in PD patients compared to the general population. In addition, Korten et al have found only eight individuals with PD among 1,516 stroke patients, which are significantly lower than the expected 30 PD patients [6].

However, the reason for the reduced stroke risk in this patient population is uncertain. There are mounting evidences to support that lipids and lipoproteins are closely linked to stroke [7,8]. The modification of lipids and lipoproteins may contribute to the reduced risk of stroke in PD patients. It is known that high blood levels of lipoproteins such as very low density lipoprotein (VLDL) and low density lipoprotein (LDL) transport triglycerides and cholesterol to peripheral blood vessels and accelerate the development of atherosclerosis. It has been shown that total cholesterol (TC), triglyceride (TG),
high density lipoprotein cholesterol (HDL-C), very low density lipoprotein cholesterol (VLDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein A (apo A), apolipoprotein B (apo B) and other lipids are associated with stroke [7–10]. The modification of TG may be related to the low incidence of stroke in PD patients. It is known that a series of lipids and lipoproteins are associated with stroke. Other lipids and lipoproteins may be also related to the decreased prevalence of stroke in patients with PD. However, more studies are required to clarify the change of lipids and lipoproteins in PD patients.

Here, we performed a retrospective study to explore the serum levels of lipids and lipoproteins in PD patients.

Methods

All patients were identified retrospectively as inpatients from 2007 to 2013 at the first affiliated hospital of Anhui Medical University. PD patients (PD group) who met the Calne’s criteria of clinically definitive PD [12] were selected consecutively in this study, and patients with atypical degenerative parkinsonisms, secondary parkinsonisms, severe liver disease, severe kidney disease, cancer, vomiting, anorexia, a history of using lipid-regulators or lack of lipids records were excluded. 110 PD patients were included in PD group (male, 62; female, 48; mean age, 67.07±8.74 years). Disease severity according to the Hoehn and Yahr scale [13] was stage I in 30 patients, stage II in 20, stage iii in 44, stage iv in 14, stage vi in 2. Controls with other non-cerebrovascular neurological diseases (OD group), patients with an initial acute intracerebral hemorrhage (ICH group) and patients with an initial acute cerebral infarction (CI group) were chosen by single-blinding method. 130 OD group patients (male, 77; females, 53; mean age, 64.98±10.72 years), 140 ICH group patients (males,83; females, 57; mean age, 64.51±11.60 years) and 140 CI group patients (males, 80; females, 60; mean age, 65.44±11.72 years) were included in this study. The non-cerebrovascular neurological diseases of OD group patients included viral encephalitis, Tolosa-Hunt syndrome, myasthenia gravis, cervical spondylotic myelopathy, lumbar disc herniation, epilepsy and other disorders. The serum levels of TC, TG, HDL-C, VLDL-C, LDL-C, apo A, apo B and lipoprotein a (LP (a)) were determined. Our study was approved by The Anhui Medical University Ethics Committee, and written consents were given by all the patients for their information to be stored in the hospital database and used for research. Anonymized data were used for the statistical analyses.

All the statistical analyses were performed with the SPSS 19.0 for Windows (SPSS, Chicago, IL) and the statistical significance was set at p<0.05. The measurement data were presented as Means ± SD. Chi-square test was used for the comparison of enumeration data. The differences of age among groups were determined with one-way analysis of variance (ANOVA). The univariate general linear model (GLM) was used to test the differences of lipids and lipoproteins between groups holding constant gender, age and the history of hypertension, diabetes mellitus ,coronary artery disease. LSD (least significant difference) method was performed for post-hoc comparisons of all groups based on estimated marginal means.

Results

The demographics, history of hypertension, diabetes mellitus, coronary artery disease of the four groups were showed in Table 1. There was no significant difference among groups in age (F = 1.244, p = 0.293), gender (χ² = 0.338, χ² = 0.953) and history of hypertension (χ² = 1.288, p = 0.732), diabetes mellitus (χ² = 0.973, p = 0.808), coronary artery disease (χ² = 1.435, p = 0.697).

As shown in Table 2, Table 3 and Table 4, the serum level of TG was 1.14±0.74 mmol/L in PD group, 1.45±0.86 mmol/L in OD group, 1.65±1.38 mmol/L in ICH group and 1.61±1.16 mmol/L in CI group. The serum levels of TG for the four groups were significantly different (F = 5.031, p = 0.002). PD patients had a significantly lower serum level of TG than subjects in the

---

Table 1. The demographics, history of coronary artery disease, hypertension, diabetes mellitus of the four groups.

|                | PD (n=110) | OD (n=130) | ICH (n=140) | CI (n=140) | χ²/F | p     |
|----------------|------------|------------|-------------|------------|------|-------|
| Age(year)      | 67.07±8.74 | 64.98±10.72| 64.51±11.60 | 65.44±11.72| 1.244| 0.293 |
| Gender(M/F)    | 62/48      | 77/53      | 83/57       | 80/60      | 0.338| 0.953 |
| Hypertension(Y/N)| 43/67     | 47/83      | 60/80       | 56/84      | 1.288| 0.732 |
| Diabetes mellitus(Y/N)| 7/103 | 8/122      | 7/133       | 11/129     | 0.973| 0.808 |
| Coronary artery disease(Y/N) | 2/108 | 2/128      | 5/135       | 4/136      | 1.435| 0.697 |

PD: Parkinson’s disease group; OD: other non-cerebrovascular neurological diseases group; ICH: intracerebral hemorrhage patients group; CI: cerebral infarction patients group; n: numbers; M: male; F: female; Y: yes (ill with this disease); N: no (not ill with this disease); χ²: Chi-square test value; F: one-way analysis of variance value.
There was a significantly lower serum level of apo B in the PD group than in the OD (p = 0.00047). But no significant difference between the PD group and OD group (p=0.142).

The serum LDL-C level was 2.55±0.83 mmol/L in PD group, 2.71±0.71 mmol/L in OD group, 2.69±0.92 mmol/L in ICH group and 3.15±1.08 mmol/L in CI group. The serum levels of LDL-C for the four groups were significantly different (F = 12.428, p<0.0001) and in the CI group (p<0.0001) (Figure 3). Serum levels of apo B were lower in the OD group than in CI group and in the CI group, but the difference was only significant when compared to the CI group (p=0.00012).

The serum level of TC was 4.41±0.98 mmol/L in PD group, 4.58±0.80 mmol/L in OD group, 4.73±1.01 mmol/L in ICH group and 5.03±1.12 mmol/L in CI group. The serum levels of TC for the four groups were significantly different (F = 12.428, p<0.0001). The LDL-C serum levels were significantly lower in PD group than in CI group(p<0.0001) and in the CI group (p=0.011). But there was no significant difference between the PD group and OD group (p=0.142).

Reduced TG, VLDL-C and Apo B in PD Patients

| Table 4. The post-hoc comparisons of lipids and lipoproteins in the four groups. |
| --- |
| **PD VS OD** | **TG** | **HDL-C** | **VLDL-C** | **LDL-C** | **APOA** | **APOB** | **LP(a)** |
| PD | 0.142 | 0.032 | 0.099 | 0.039 | 0.147 | 0.773 | 0.002 | 0.438 |
| OD | 0.011 | 0.00047 | 0.380 | 0.00021 | 0.221 | 0.030 | <0.0001 | 0.388 |
| CI | <0.0001 | 0.001 | 0.032 | 0.001 | <0.0001 | 0.766 | <0.0001 | 0.005 |
| OD VS CI | 0.00022 | 0.244 | 0.623 | 0.251 | <0.0001 | 0.536 | 0.00012 | 0.033 |
| CI VS CI | 0.008 | 0.809 | 0.001 | 0.568 | <0.0001 | 0.046 | 0.003 | 0.036 |

The results were adjusted for gender, age and the history of hypertension, diabetes mellitus, coronary artery disease using univariate general linear model.

| Table 2. The serum levels of lipids and lipoproteins in the four groups. |
| --- |
| **PD** | **OD** | **ICH** | **CI** |
| **TC** (mmol/L) | 4.41±0.98 | 4.58±0.80 | 4.73±1.01 | 5.03±1.12 |
| **TG** (mmol/L) | 1.14±0.74 | 1.45±0.36 | 1.65±1.38 | 1.61±1.16 |
| **VLDL-C** (mmol/L) | 0.42±0.28 | 0.54±0.32 | 0.63±0.53 | 0.60±0.43 |
| **LDL-C** (mmol/L) | 2.55±0.83 | 2.71±0.71 | 2.69±0.92 | 3.15±1.08 |
| **HDL-C** (mmol/L) | 1.44±0.40 | 1.34±0.47 | 1.47±0.43 | 1.31±0.39 |
| **Apo A** (g/L) | 1.33±0.31 | 1.32±0.34 | 1.42±0.37 | 1.34±0.32 |
| **Apo B** (g/L) | 0.80±0.21 | 0.89±0.20 | 0.92±0.31 | 1.01±0.25 |
| **LP(a)** (mg/L) | 170.62±171.92 | 188.04±158.12 | 191.66±182.79 | 236.17±201.99 |

PD: Parkinson’s disease group; OD: other non-cerebrovascular neurological diseases group; ICH: intracerebral hemorrhage patients group; CI: cerebral infarction patients group; TC: total cholesterol; TG: triglyceride; VLDL-C: very low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; Apo A: apolipoprotein A; Apo B: apolipoprotein B; LP(a): lipoprotein a.

doi: 10.1371/journal.pone.0075743.t002

| Table 3. The results of univariate general linear model for lipids and lipoproteins in the four groups. |
| --- |
| **TC** | **TG** | **HDL-C** | **VLDL-C** | **LDL-C** | **Apo A** | **Apo B** | **LP(a)** |
| F | 9.342 | 5.031 | 4.449 | 5.313 | 12.428 | 2.721 | 16.038 | 3.095 |
| *p* | <0.0001 | 0.002 | 0.004 | 0.001 | <0.0001 | 0.044 | <0.0001 | 0.027 |

The results were adjusted for gender, age and the history of hypertension, diabetes mellitus, coronary artery disease using univariate general linear model.

* p < 0.05; PD: total cholesterol; TG: triglyceride; VLDL-C: very low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; Apo A: apolipoprotein A; Apo B: apolipoprotein B; LP(a): lipoprotein a.

doi: 10.1371/journal.pone.0075743.t003
serum level of HDL-C was observed when the PD group compared with OD group \( (p=0.099) \), ICH \( (p=0.380) \). The HDL-C serum level was significantly higher in PD group than in CI group \( (p=0.032) \).

The serum level of apo A was \( 1.33\pm0.31 \text{ g/L} \) in PD group, \( 1.32\pm0.34 \text{ g/L} \) in the OD group, \( 1.42\pm0.37 \text{ g/L} \) in ICH group and \( 1.34\pm0.32 \text{ g/L} \) in CI group. The serum levels of apo A for the four groups were not significantly different \( (F=2.721, p=0.044) \). The apo A serum level was significantly lower in PD group than in ICH group \( (p=0.030) \), but not in OD group \( (p=0.773) \) and in CI group \( (p=0.776) \).

The serum level of LP (a) was \( 170.62\pm171.92 \text{ mg/L} \) in PD group, \( 188.04\pm158.12 \text{ mg/L} \) in OD, \( 191.66\pm182.79 \text{ mg/L} \) in ICH and \( 236.17\pm201.99 \text{ mg/L} \) in the CI groups. There was significantly difference for the LP (a) serum levels of the four groups \( (F=3.095, p=0.027) \). The serum level of LP (a) was significantly lower in PD group than in CI group \( (p=0.005) \), but no significant difference was observed when PD group compared with OD group \( (p=0.438) \) and ICH group \( (p=0.388) \).

**Discussion**

High plasma levels of lipids and lipoproteins and low levels of HDL-cholesterol are established risk factors for stroke [7,8]. Our goal was to find the lipids and lipoproteins that may contribute to the reduced incidence of stroke in PD patients. In this study, we have adjusted the age, gender and the history of hypertension, diabetes mellitus, coronary artery disease among the four groups to avoid the biases of these confounding factors. Finally, we find that the serum levels of TG, VLDL-C and apo B are the most remarkable indexes that are significantly lower in PD group than in OD, CI and ICH groups.

The possible relationship between serum TG level and stroke has been investigated in various studies. In a systematic review, Labreuche et al have found a positive association between TG and stroke [14]. Many researchers have also performed case control studies to investigate the level of TG in stroke patients compared with other non-cerebrovascular diseases patients or health control, and TG has been identified...
as a risk factor for stroke [15-17]. Scigliano et al also found low level of plasma TG in PD patients which was consistent with our study [11]. Taken together, these data suggest that decreased risk of stroke in PD patients could be related to low level of TG in these patients.

VLDL is an independent risk factor for atherosclerosis and has been associated with the incidence of stroke [18,19]. VLDL transport triglyceride (VLDL-T) and cholesterol (VLDL-C) from the liver to the target tissues, including peripheral blood vessels. One study has shown that vaccination with VLDL to induce neonatal tolerance can protect endothelial cells and reduce the accumulation of lipids in rats [20]. It has been reported that VLDL-C is significantly associated with the thickness of the intima media of the common carotid artery, which reflects the degree of arteriostenosis [21]. In case control studies, significantly higher levels of VLDL-C have also been found in stroke patients than in health controls [10,22]. In our study, the serum level of VLDL-C is significantly lower in the PD group than the other three groups. These results indicate that lower VLDL-C may contribute to the reduced stroke risk in PD patients.

Apo B is a main structural protein of the VLDL, LDL and chylomicrons. The apo B-containing lipoproteins transport lipids from the liver and intestine to the sites of utilization, such as blood vessels. When the apo B-containing lipoproteins reach the endothelial and smooth muscles of blood vessels, the process of arteriosclerosis which is an important risk factor of stroke is initiated [23-25]. It has been demonstrated that high levels of apo B-containing lipoproteins such as VLDL and LDL promote the development of arteriosclerosis [26]. The apo B level is the representation of apo B-containing lipoproteins, i.e., a higher level of apo B indicates higher levels of VLDL and LDL. These transport more TC and TG to the blood vessels and lead to more severe arteriosclerosis. Epidemiological studies have already demonstrated this and shown that increased levels of apo B is a risk factor of stroke [9,27].

Figure 2. The serum level of Very low density lipoprotein cholesterol (VLDL-C) in the four groups. Very low density lipoprotein cholesterol (VLDL-C) serum level was significantly lower in PD group than in OD (p=0.039), ICH (p=0.00021) and CI (p=0.001) groups.

PD: Parkinson’s disease group; OD: other non-cerebrovascular neurological diseases group; ICH: intracerebral hemorrhage patients group; CI: cerebral infarction patients group.

doi: 10.1371/journal.pone.0075743.g002
study, the serum level of apo B was significantly lower in the PD group. These results suggest that a lower level of apo B may also contribute to the decreased prevalence of stroke in PD patients.

As the core protein of VLDL, a reduced serum level of apo B is consistent with the reduced serum level of VLDL-C in PD patients. The majority of TG is transported by VLDL, which is rich of TG. The reduced serum level of TG indicates a reduced serum level of VLDL, which leads to a reduced serum level of apo B. We found that the serum levels of all the substances were significantly lower in the PD patients than the control subjects, which is consistent with the close relationship among them. According to the discussion above, we hypothesize that the synergetic effect of reduced TG, VLDL-C and apo B in serum leads to a lower incidence and a slower progression of arteriosclerosis, which results in a lower prevalence of stroke in PD patients.

Nutrition contributes to the lipid profile. Van der Marck et al have concluded that PD patients have a significantly lower body mass index (BMI) than controls in a meta-analysis [28], but Barichella et al have reported that nutrition is generally normal in PD patients [29]. So it needs further research to explore the relationship between nutrition and the changes of lipids and lipoproteins in PD patients.

Scigliano et al have suggested that these changes may be related to the reduced sympathetic activity that characterizes PD [11]. In that study, authors have found TG levels in PD patients have significantly lower than in the control group which is consistent with reduced catecholamine, cortisol production. But Berg et al have found that the serum concentration of apo B-containing lipoproteins could not be regulated by cortisol and catecholamines, and adrenocorticotrophic hormone (ACTH) could reduce the serum concentration of apo B-containing lipoproteins [30]. One study has reported that ACTH is significantly lower in untreated PD patients than in health...
control group [31]. According to above studies, there may be a higher serum concentration of apo B-containing lipoproteins in PD patients. But the study is performed on untreated PD patients, which could not represent the real state in treated PD patients, especially the effect of levodopa. Levodopa can be converted into dopamine by enzymes in peripheral tissues, and one study has reported that dopamine could decrease serum TG level [32]. Consistently, Scigliano et al have already found evidences suggest that levodopa may play a key role in the changes of lipids and lipoproteins in PD patients.

For further research, it is important to confirm that levodopa could regulate lipids and lipoproteins in PD patients. Well-designed randomized self controlled studies need to be performed which aim to clarify the changes of lipids and lipoproteins in PD patients before and after treatment. On the basis, researchers should pay more attention to molecular mechanisms of lipids and lipoproteins regulated by levodopa, which may extend to new lipids regulatory mechanism and effective lipid regulators. Also, nutrition, as a controversial role in the metabolism of lipids and lipoproteins in PD patient, need more studies to identify the exact role.

Conclusions

There are reduced serum levels of TG, VLDL-C and apo B in PD patients, which may be related to the decreased prevalence of stroke in PD patients.

Author Contributions

Conceived and designed the experiments: KW. Performed the experiments: QW HHW. Analyzed the data: QW HHW. Contributed reagents/materials/analysis tools: YHT FCX XWC. Wrote the manuscript: KW.

References

1. Nutt JG, Wooten GF (2005) Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 353: 1021-1027. doi:10.1056/NEJMcp043908. PubMed: 16148287.

2. Pfeiffer RF (2009) Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study. Nat Rev Neurol 5: 531-532. doi:10.1038/nrneurol.2009.156.

3. Levine RL, Jones JC, Bee N (1992) Stroke and Parkinson’s disease. Stroke 23(6): 839-842. doi:10.1161/01.STR.23.6.839. PubMed: 1595102.

4. Struck LK, Rodnitzky RL, Dobson JK (1990) Stroke and its modification in Parkinson’s disease. Stroke 21: 1395-1399. doi:10.1161/01.STR.21.10.1935. PubMed: 2219202.

5. Nataraj A, Rajput AH (2005) Parkinson’s disease, stroke, and related epidemiology. Mov Disord 20: 1476-1480. doi: 10.1002/mds.20608. PubMed: 16037916.

6. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L et al. (2001) Stroke and idiopathic Parkinson’s disease. Does a shortage of dopamine offer protection against stroke? Mov Disord 16: 119-123. doi:10.1002/1531-8257(200101)16:1. PubMed: 11215570.

7. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J (1997) Status of lipids as a risk factor for stroke. Neuroepidemiology 16: 107-115. doi:10.1159/000109679. PubMed: 9159765.

8. Benson RT, Sacco RL (2000) Stroke prevention: hypertension, diabetes, tobacco, and lipids. Neurul Clin 18(2): 309-319. doi:10.1016/S0703-8619(05)70194-8. PubMed: 10757828.

9. Holme I, Aastveit AH, Hammar N, Jungrner I, Walldius G (2009) Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein Mortality Risk study (AMORIS). J Intern Med 265: 275-287. doi:10.1111/j.1365-2966.2008.01206.x. PubMed: 19011984.

10. Murai A, Miyahara T, Tanaka T, Kamayama M (1986) Characterization of plasma lipoproteins in survivors of cerebral infarction. Tohoku J Exp Med 148: 57-64. doi:10.2484/tjem.148.57. PubMed: 3705506.

11. Scigliano G, Musico M, Soliveri P, Piccolo I, Ronchetti G et al. (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: A case-control study. Stroke 37: 1184-1188. doi:10.1161/01.STR.0000217384.03237.9c. PubMed: 16574924.

12. Caine DB, Snow BJ, Lee C (1992) Criteria for diagnosing Parkinson’s disease. Ann Neurol 32. Suppl: S125–S127. doi:10.1002/ana.1030721. PubMed: 1510370.

13. Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17: 427-442. doi:10.1212/wnl.17.5.427. PubMed: 6067254.

14. Labreuche J, Touboul PJ, Amarenco P (2009) Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 203: 331-345. doi:10.1016/j.atherosclerosis.2008.08.040. PubMed: 18954872.

15. Laloux P, Galanti L, Jamart J (2004) Lipids in ischemic stroke subtypes. Acta Neurol Belg 104: 13-19. PubMed: 15143967.

16. Ahmed E, Trifunovic J, Stegmayr B, Hallmans G, Lefvert AK (1999) Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke 30: 2541-2546. doi:10.1161/01.STR.30.12.2541. PubMed: 10582975.

17. Wuu J, Lau E, Lam CW, Kay R, et al. (1991) Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke 22: 203-208. PubMed: 1625896.

18. Cannon CP (2008) Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol 102: S-L. doi:10.1016/j.amjcard.2008.09.067. PubMed: 19094063.

19. Krauss RM (1998) Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 81: 13B-17B. doi:10.1016/S0002-9149(98)00047-2. PubMed: 9528808.

20. Cui K, Hou G, Feng Y, Liang T, Kong F et al. (2012) The potential role of preventing atherosclerosis by induction of neonatal tolerance to VLDL. Cell Immunol 272: 290-292. doi:10.1016/j.cellimm.2011.09.013. PubMed: 22067889.

21. Norata GD, Raselli S, Grigore L (2009) Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 206: 556-562. doi:10.1016/j.atherosclerosis.2009.03.017. PubMed: 19376517.

22. Shieh SM, Shen MM, Tsai WJ, Shiuan LR, Wang DJ (1985) Serum lipids and lipoprotein abnormalities in patients with thrombotic stroke--with exploring the protective role of HDL subclassses. Proc Natl Sci Counc Repub China B 9. pp. 298-304.

23. Olofsson SO, Beren J (2005) Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 258: 395-410. doi:10.1111/j.1365-2966.2005.01556.x. PubMed: 16238675.

24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421. PubMed: 12485966.

25. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ et al. (2005) Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112: 3375-3383. doi:10.1161/CIRCULATIONAHA.104.532499. PubMed: 16316964.

26. Goldberg IJ (1996) Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37: 693-707.

27. Bhatia M, Howard SC, Clark TG, Neale R, Qizilbash N et al. (2006) Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack. Cerebrovasc Dis 21: 323-328. doi: 10.1159/000091537. PubMed: 16490941.
28. van der Marck MA, Dicke HC, Uc EY, Kentin ZH, Borm GF et al. (2012) Body mass index in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord 18(3): 263-267. doi:10.1016/j.parkreldis.2011.10.016. PubMed: 22100523.

29. Barichella M, Marczewska A, Vairo A, Canesi M, Pezzoli G (2003) Is underweightness still a major problem in Parkinson’s disease patients? Eur J Clin Nutr 57: 543-547. doi:10.1038/sj.ejcn.1601581. PubMed: 12700615.

30. Berg AL, Rafnsson AT, Johannsson M, Dallongeville J, Arnadottir M. (2006) The effects of adrenocorticotropic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins Metabolism 55: 1083–7.

31. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G (1991) Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson’s disease. J Neurol 238(1): 19-22. doi:10.1007/BF00319704. PubMed: 1851513.

32. Kimura T, Hasegawa M, Takano O (2002) [The effect of dopamine on serum lipid concentration after propofol administration]. Masui 51(3): 286-288. PubMed: 11925896.

33. Scigliano G, Ronchetti G, Girotti F, Musicco M (2009) Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord 15(2): 138-143. doi:10.1016/ j.parkreldis.2008.04.036. PubMed: 18556236.